Latest research on Mirtazapine

Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. [Wikipedia]

Latest findings

The antidepressant types were divided into three categories: i) selective serotonin reuptake inhibitors including Citalopram, esCitalopram, fluoxetine, Paroxetine, and Sertraline, ii) newer antidepressants such as Bupropion, Venlafaxine, and Mirtazapine, and iii) older anti-depressants such as Amitriptyline, Clomipramine, Imipramine, Milnacipran, Nortriptyline, tianeptine, and Trazodone. [source, 2016]
Several pharmacological therapies for insomnia have been formulated, including benzodiazepine receptor antagonists (BzRAs) (eg, benzodiazepines and nonbenzodiazepine sedative-hypnotics, such as Zolpidem, Zaleplon, and Eszopiclone), Melatonin, Melatonin-receptor agonists, and various antidepressant medications including Quetiapine, Amitriptyline, Mirtazapine, and Trazodone. [source, 2016]
Various treatment options exist for HIV wasting syndrome and include appetite stimulants (Megestrol Acetate, Dronabinol, and Mirtazapine), anabolic agents (testosterone, testosterone analogs, and recombinant human Growth hormone [rhGH]), and, rarely, cytokine production modulators (Thalidomide). [source, 2016]
Although not approved for HIV wasting syndrome, Mirtazapine is a tetracyclic antidepressant that is available as an oral tablet or an orally disintegrating tablet. [source, 2016]
Despite weight gain being reported as a common adverse effect of Mirtazapine, it is for this reason that Mirtazapine may be considered in HIV wasting syndrome in patients with concomitant depression. [source, 2016]
One study evaluated the use of Mirtazapine in HIV-positive patients and found a 3 kg increase in TBW over a period of 12 weeks. [source, 2016]
Although the sample size was relatively small and duration of study was short, it demonstrated that Mirtazapine may be another treatment option for managing weight loss in HIV patients with depression. [source, 2016]
Appetite stimulation associated with Mirtazapine use is thought to be secondary to blocking serotonin 5-HT1b and 5-HT2 receptors as well as inhibiting the release of neuropeptide Y. [source, 2016]
Mirtazapine has also been associated with antiemetic effects through inhibition of 5-HT3 receptors. [source, 2016]
It is recommended to initiate Mirtazapine at 15 mg daily and titrate to effect. [source, 2016]